Share：
Share this content in WeChat
X
[Chinese][PDF]103931
• Clinical Article •
Correlation analysis of breast MRI-based background parenchymal enhancement with different molecular subtypes and clinical factors of breast cancer
WU Di  GAO Qian  GAO Chao  LUO Chunyan  JIANG Jie  LIU Xiaoying  LI Jun 

Cite this article as: Wu D, Gao Q, Gao C, et al. Correlation analysis of breast MRI-based background parenchymal enhancement with different molecular subtypes and clinical factors of breast cancer[J]. Chin J Magn Reson Imaging, 2022, 13(5): 40-44. DOI:10.12015/issn.1674-8034.2022.05.008.


[Abstract] Objective To explore the correlation between the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) background parenchymal enhancement (BPE) characteristics and different molecular subtypes of breast cancer.Materials and Methods Retrospective analysis from 2019 to 2020 clinical and imaging data of patients undergoing breast magnetic resonance examination in our hospital. Select the first phase image evaluation of BPE after the contrast medium injection in DCE-MRI. Use Spearman's correlation test to compare BPE correlation with various clinical factors; χ2 test was used to compare the degree of BPE with different molecular subtypes of breast cancer, the difference between menopause or not.Results One hundred and ninety-nine cases were enrolled, of which 32 were Luminal A, 118 cases of Luminal B [Luminal B (HER-2 positive) 48 cases, Luminal B (HER-2 negative) 70 cases], 24 cases of HER-2 overexpression type, 25 cases of basal-like type. BPE has negative correlation with the patient's age, weight, and body mass index (BMI) (P＜0.05); BPE has no significant correlation with the patient's height; BPE has a positive correlation with the patient's menopause (P＜0.01), the BPE of menopausal patients is mainly minimal or mildly enhanced, and the BPE of non-menopausal patients is mainly mild or moderate enhancement, some were severe enhancement, and the difference was statistically significant (P＜0.01). BPE degree and the molecular subtypes of breast cancer were correlated (P＜0.05), but the results of the analysis showed no statistically significant difference among the groups (P=0.162); the combined degree of BPE was divided into minimal+mild, moderate+severe enhancement, the results showed that there was no difference in the degree of BPE among the molecular subtype groups (P=0.298).Conclusions There has a correlation between BPE with patient's age, weight, BMI, menopause or not. And the BPE is connected with the molecular subtypes of breast cancer, but there is no difference between the groups after grouping.
[Keywords] magnetic resonance imaging；dynamic contrast-enhanced；breast cancer；background parenchymal enhancement；molecular subtypes

WU Di   GAO Qian   GAO Chao   LUO Chunyan   JIANG Jie   LIU Xiaoying   LI Jun*  

Department of Medical Imaging, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, China

Li J, E-mail: hhbt0356@sina.com

Conflicts of interest   None.

ACKNOWLEDGMENTS Basic Research Plan of Yunnan Science and Technology Plan Project (Special Project of Kunming Medical Association, No. 202101AY070001-101); Yunnan High-level Health Technical Personnel Training Program (No. H-2018007).
Received  2022-01-21
Accepted  2022-04-29
DOI: 10.12015/issn.1674-8034.2022.05.008
Cite this article as: Wu D, Gao Q, Gao C, et al. Correlation analysis of breast MRI-based background parenchymal enhancement with different molecular subtypes and clinical factors of breast cancer[J]. Chin J Magn Reson Imaging, 2022, 13(5): 40-44. DOI:10.12015/issn.1674-8034.2022.05.008.

[1]
Siegel RL, Miller KD, Sauer AG, et al. Colorectal cancer statistics, 2020[J]. Ca Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21601.
[2]
Breast Cancer Expert Committee of National Cancer Quality Control Center. Quality control index for standardized diagnosis and treatment of breast cancer in China (2022 Edition)[J]. Chin J Oncol, 2022, 44(3): 203-208. DOI: 10.3760/cma.j.cn112152-20220104-00008.
[3]
Mercado CL. BI-RADS update[J]. Radiol Clin North Am, 2014, 52(3): 481-487. DOI: 10.1016/j.rcl.2014.02.008.
[4]
Bae SJ, Cha YJ, Na LE, et al. Diagnostic Accuracy of Nonmass Enhancement at Breast MRI in Predicting Tumor Involvement of the Nipple: A Prospective Study in a Single Institution[J]. Radiology, 2021, 301(1): 47-56. DOI: 10.1148/radiol.2021204136.
[5]
Xiao Q, Gu YJ. Role of imaging in evaluating neoajubant chemotherapy for breast cancer[J]. Oncoradiology, 2020, 29(2): 65-72. DOI: 10.19732/j.cnki.2096-6210.2020.01.001.
[6]
You C,Peng WJ,Gu YJ,et al. The diagnostic value of both mammography and MRI in combination with clinical features in high-risk breast lesions[J]. Chin J Radiol, 2020, 54(3): 203-208. DOI: 10.3760/cma.j.issn.1005-1201.2020.03.006.
[7]
Zhang R, Yang XP. Research progress of background parenchymal. enhancement in breast magnetic resonance imaging[J]. Chin J Magn Reson Imaging, 2021, 12(3): 102-104, 108. DOI: 10.12015/issn.1674-8034.2021.03.025.
[8]
Onishi N, Li W, Newitt DC, et al. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response[J]. Radiology, 2021, 301(2): 295-308. DOI: 10.1148/radiol.2021203645.
[9]
Vreemann S, Gubern-Mérida A, Borelli C, et al. The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers[J]. PLoS One, 2018, 13(1): e0191399. DOI: 10.1371/journal.pone.0191399.
[10]
You C, Gu YJ, Hu XX, et al. The value of background parenchymal enhancement in assessing the molecular subtype of breast cancer[J]. Oncoradiology, 2020, 29(2): 79-84. DOI: 10.19732/j.cnki.2096-6210.2020.02.003.
[11]
Ha R, Mango V, Al-Khalili R, et al. Evaluation of association between degree of background parenchymal enhancement on MRI and breast cancer subtype[J]. Clin Imaging, 2018, 51: 307-310. DOI: 10.1016/j.clinimag.2018.05.008.
[12]
Wu J, Sun X, Wang J, et al. Identifying relations between imaging phenotypes and molecular subtypes of breast cancer: Model discovery and external validation[J]. J Magn Reson Imaging, 2017, 46(4): 1017-1027. DOI: 10.1002/jmri.25661.
[13]
Devalapalli A, Thomas S, Mazurowski MA, et al. Performance of preoperative breast MRI based on breast cancer molecular subtype[J]. Clin Imaging, 2020, 67: 130-135. DOI: 10.1016/j.clinimag.2020.05.017.
[14]
Dilorenzo G, Telegrafo M, La Forgia D, et al. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type[J]. Eur J Radiol, 2019, 113: 148-152. DOI: 10.1016/j/ejrad.2019.02.018.
[15]
Zhang M, Sadinski M, Haddad D, et al. Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score[J]. Front Oncol, 2021, 10: 595820. DOI: 10.3389/fonc.2020.595820.
[16]
Morris EA, Comstock C, Lee C, et al. BI-RADS: magnetic resonance imaging 2013[M]//D'Orsi CJ, Sickles EA, Mendelson EB, et al. Breast Imaging Reporting and Data System: ACR BI-RADS, breast imaging atlas. Reston: American College of Radiology. 2013: 29-32.
[17]
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer[J]. J Clin Oncol, 2010, 28(16): 2784-2795. DOI: 10.1200/JCO.2009.6529.
[18]
Curigliannno G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017[J]. Ann Oncol, 2017, 28(8): 1700-1712. DOI: 10.1093/annonc/mdx308.
[19]
Jung Y, Jeong S, Kim JY, et al. Correlations of female hormone levels with background parenchymal enhancement and apparent diffusion coefficient values in premenopausal breast cancer patients: Effects on cancer visibility[J]. Eur J Radiol, 2020, 124: 108818. DOI: 10.106/j.ejrad.2020.108818.
[20]
Brooks JD, Sung JS, Pike MC, et al. MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women[J]. Int J Cancer, 2018, 143(4): 823-830. DOI: 10.1002/ijc.31370.
[21]
Heller SL, Young Lin LL, Melsaether AN, et al. Hormonal Effects on Breast Density, Fibroglandular Tissue, and Background Parenchymal Enhancement[J]. Radiographics, 2018, 38(4): 983-996. DOI: 10.1148/rg.2018180035.
[22]
Arasu VA, Miglioretti DL, Sprague BL, et al. Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk[J]. J Clin Oncol, 2019, 37(12): 954-963. DOI: 10.1200/JCO.18.00378.
[23]
Watt GP, Sung J, Morris EA, et al. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study[J]. Breast Cancer Res, 2020, 22(1): 138. DOI: 10.1186/s13058-020-01375-7.
[24]
Stephen V, Ronco AJ, Elham N, et al. Screening Breast MRI and the Science of Premenopausal Background Parenchymal Enhancement[J]. J Breast Imaging, 2021, 3(4): 407-415. DOI: 10.1093/jbi/wbab045.
[25]
Chen S, Peng SY, Chen YQ, et al. Research progresses of breast background parenchymal enhancement of MRI[J]. J Clin Radiol, 2020, 39(6): 1235-1238. DOI: 10.13437/j.cnki.jcr.2020.06.046.
[26]
Hellgren R, Saracco A, Strand F, et al. The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI[J]. Acta Radiol, 2020, 61(12): 1600-1607. DOI: 10.1177/0284185120911583.
[27]
Jiang C, Zhang SY, Huang YX. Relationship between body mass index and pathological complete remission to neoadju-vant chemotherapy for HER-2 positive breast cancer[J]. J Modern Oncol, 2020, 28(11): 1881-1884. DOI: 10.3969/j.issn.1672-4992.2020.11.016.
[28]
Pearson-Stuttard J, Zhou B, Kontis V, et al. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment[J]. Lancet Diabetes Endocrinol, 2018, 6(2): 95-104. DOI: 10.1016/S2213-8587(17)30336-2.
[29]
Lee CH, Bryce Y, Zheng J, et al. Outcome of Screening MRI in Premenopausal Women as a Function of the Week of the Menstrual Cycle[J]. AJR Am J Roentgenol, 2020, 214(5): 1175-1181. DOI: 10.2214/AJR.18.19960.
[30]
Dontchos BN, Rahbar H, Partridge SC, et al. Influence of Menstrual Cycle Timing on Screening Breast MRI Background Parenchymal Enhancement and Diagnostic Performance in Premenopausal Women[J]. J Breast Imaging, 2019, 1(3): 205-211. DOI: 10.1093/jbi/wbz022.

PREV Clinical application value of MR-based radiomics for differentiation of benign and malignant of parotid gland
NEXT Value of a nomogram based on MRI, mammography and pathology for predicting sentinel lymph node metastasis of mass-type breast invasive ductal carcinoma
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn